CING
Cingulate IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$64.31M
P/E Ratio
—
EPS
$-4.44
Beta
-0.81
52W High
$11.89
52W Low
$3.20
50-Day MA
$6.47
200-Day MA
$4.94
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders. The company is headquartered in Kansas City, Kansas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-9.77M |
| EBITDA | $-19.40M |
| Operating Margin | 0.00% |
| Return on Equity | -450.60% |
| Return on Assets | -83.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.35 |
| Price-to-Book | 26.22 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $12.25M |
| Float | $11.29M |
| % Insiders | 33.56% |
| % Institutions | 4.76% |
Historical Volatility
HV 10-Day
86.94%
HV 20-Day
78.48%
HV 30-Day
75.61%
HV 60-Day
125.46%
HV Rank
56.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($28.70 target)
1
Strong Buy2
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026